#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-9	Intrinsic	_
1-2	10-22	connectivity	_
1-3	23-31	patterns	_
1-4	32-34	of	_
1-5	35-47	task-defined	_
1-6	48-53	brain	_
1-7	54-62	networks	_
1-8	63-68	allow	_
1-9	69-79	individual	_
1-10	80-90	prediction	_
1-11	91-93	of	_
1-12	94-103	cognitive	_
1-13	104-111	symptom	_
1-14	112-121	dimension	_
1-15	122-124	of	_
1-16	125-138	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-17	139-142	and	_
1-18	143-146	are	_
1-19	147-153	linked	_
1-20	154-156	to	_
1-21	157-166	molecular	_
1-22	167-179	architecture	_
1-23	180-190	Background	_
1-24	191-192	:	_
1-25	193-200	Despite	_
1-26	201-204	the	_
1-27	205-211	marked	_
1-28	212-228	inter-individual	_
1-29	229-240	variability	_
1-30	241-243	in	_
1-31	244-247	the	_
1-32	248-256	clinical	_
1-33	257-269	presentation	_
1-34	270-272	of	_
1-35	273-286	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-36	287-288	,	_
1-37	289-291	it	_
1-38	292-299	remains	_
1-39	300-307	unclear	_
1-40	308-311	the	_
1-41	312-318	extent	_
1-42	319-321	to	_
1-43	322-327	which	_
1-44	328-338	individual	_
1-45	339-349	dimensions	_
1-46	350-352	of	_
1-47	353-368	psychopathology	_
1-48	369-375	relate	_
1-49	376-378	to	_
1-50	379-382	the	_
1-51	383-393	functional	_
1-52	394-405	variability	_
1-53	406-408	in	_
1-54	409-414	brain	_
1-55	415-423	networks	_
1-56	424-429	among	_
1-57	430-438	patients	_
1-58	439-440	.	_

2-1	441-445	Here	_
2-2	446-447	,	_
2-3	448-450	we	_
2-4	451-458	address	_
2-5	459-463	this	_
2-6	464-472	question	_
2-7	473-478	using	_
2-8	479-492	network-based	_
2-9	493-503	predictive	_
2-10	504-512	modeling	_
2-11	513-515	of	_
2-12	516-526	individual	_
2-13	527-542	psychopathology	_
2-14	543-548	along	_
2-15	549-553	four	_
2-16	554-565	data-driven	_
2-17	566-573	symptom	_
2-18	574-584	dimensions	_
2-19	585-586	.	_

3-1	587-596	Follow-up	_
3-2	597-605	analyses	_
3-3	606-612	assess	_
3-4	613-616	the	_
3-5	617-626	molecular	_
3-6	627-640	underpinnings	_
3-7	641-643	of	_
3-8	644-654	predictive	_
3-9	655-663	networks	_
3-10	664-666	by	_
3-11	667-675	relating	_
3-12	676-680	them	_
3-13	681-683	to	_
3-14	684-709	neurotransmitter-receptor	_
3-15	710-722	distribution	_
3-16	723-731	patterns	_
3-17	732-733	.	_

4-1	734-741	Methods	_
4-2	742-743	:	_
4-3	744-746	We	_
4-4	747-759	investigated	_
4-5	760-773	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
4-6	774-778	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
4-7	779-783	data	_
4-8	784-788	from	_
4-9	789-792	147	_
4-10	793-806	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-11	807-815	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-12	816-825	recruited	_
4-13	826-828	at	_
4-14	829-834	seven	_
4-15	835-840	sites	_
4-16	841-842	.	_

5-1	843-853	Individual	_
5-2	854-864	expression	_
5-3	865-870	along	_
5-4	871-879	negative	_
5-5	880-881	,	_
5-6	882-890	positive	_
5-7	891-892	,	_
5-8	893-902	affective	_
5-9	903-904	,	_
5-10	905-908	and	_
5-11	909-918	cognitive	_
5-12	919-926	symptom	_
5-13	927-937	dimensions	_
5-14	938-941	was	_
5-15	942-951	predicted	_
5-16	952-957	using	_
5-17	958-967	relevance	_
5-18	968-974	vector	_
5-19	975-982	machine	_
5-20	983-988	based	_
5-21	989-991	on	_
5-22	992-1002	functional	_
5-23	1003-1015	connectivity	_
5-24	1016-1022	within	_
5-25	1023-1025	17	_
5-26	1026-1039	meta-analytic	_
5-27	1040-1053	task-networks	_
5-28	1054-1063	following	_
5-29	1064-1065	a	_
5-30	1066-1074	repeated	_
5-31	1075-1082	10-fold	_
5-32	1083-1099	cross-validation	_
5-33	1100-1103	and	_
5-34	1104-1122	leave-one-site-out	_
5-35	1123-1131	analyses	_
5-36	1132-1133	.	_

6-1	1134-1141	Results	_
6-2	1142-1146	were	_
6-3	1147-1156	validated	_
6-4	1157-1159	in	_
6-5	1160-1162	an	_
6-6	1163-1174	independent	_
6-7	1175-1181	sample	_
6-8	1182-1183	.	_

7-1	1184-1192	Networks	_
7-2	1193-1201	robustly	_
7-3	1202-1212	predicting	_
7-4	1213-1223	individual	_
7-5	1224-1231	symptom	_
7-6	1232-1242	dimensions	_
7-7	1243-1247	were	_
7-8	1248-1257	spatially	_
7-9	1258-1268	correlated	_
7-10	1269-1273	with	_
7-11	1274-1281	density	_
7-12	1282-1286	maps	_
7-13	1287-1289	of	_
7-14	1290-1294	nine	_
7-15	1295-1317	receptors/transporters	_
7-16	1318-1322	from	_
7-17	1323-1328	prior	_
7-18	1329-1338	molecular	_
7-19	1339-1346	imaging	_
7-20	1347-1349	in	_
7-21	1350-1357	healthy	_
7-22	1358-1369	populations	_
7-23	1370-1371	.	_

8-1	1372-1379	Results	_
8-2	1380-1381	:	_
8-3	1382-1390	Ten-fold	_
8-4	1391-1394	and	_
8-5	1395-1413	leave-one-site-out	_
8-6	1414-1422	analyses	_
8-7	1423-1431	revealed	_
8-8	1432-1436	five	_
8-9	1437-1447	predictive	_
8-10	1448-1463	network-symptom	_
8-11	1464-1476	associations	_
8-12	1477-1478	.	_

9-1	1479-1491	Connectivity	_
9-2	1492-1498	within	_
9-3	1499-1513	theory-of-mind	_
9-4	1514-1515	,	_
9-5	1516-1525	cognitive	_
9-6	1526-1537	reappraisal	_
9-7	1538-1539	,	_
9-8	1540-1543	and	_
9-9	1544-1550	mirror	_
9-10	1551-1557	neuron	_
9-11	1558-1566	networks	_
9-12	1567-1576	predicted	_
9-13	1577-1585	negative	_
9-14	1586-1587	,	_
9-15	1588-1596	positive	_
9-16	1597-1598	,	_
9-17	1599-1602	and	_
9-18	1603-1612	affective	_
9-19	1613-1620	symptom	_
9-20	1621-1631	dimensions	_
9-21	1632-1633	,	_
9-22	1634-1646	respectively	_
9-23	1647-1648	.	_

10-1	1649-1658	Cognitive	_
10-2	1659-1668	dimension	_
10-3	1669-1672	was	_
10-4	1673-1682	predicted	_
10-5	1683-1685	by	_
10-6	1686-1700	theory-of-mind	_
10-7	1701-1704	and	_
10-8	1705-1728	socio-affective-default	_
10-9	1729-1737	networks	_
10-10	1738-1739	.	_

11-1	1740-1751	Importantly	_
11-2	1752-1753	,	_
11-3	1754-1759	these	_
11-4	1760-1771	predictions	_
11-5	1772-1783	generalized	_
11-6	1784-1786	to	_
11-7	1787-1790	the	_
11-8	1791-1802	independent	_
11-9	1803-1809	sample	_
11-10	1810-1811	.	_

12-1	1812-1824	Intriguingly	_
12-2	1825-1826	,	_
12-3	1827-1832	these	_
12-4	1833-1836	two	_
12-5	1837-1845	networks	_
12-6	1846-1850	were	_
12-7	1851-1861	positively	_
12-8	1862-1872	associated	_
12-9	1873-1877	with	_
12-10	1878-1880	D1	_
12-11	1881-1889	dopamine	_
12-12	1890-1898	receptor	_
12-13	1899-1902	and	_
12-14	1903-1912	serotonin	_
12-15	1913-1921	reuptake	_
12-16	1922-1933	transporter	_
12-17	1934-1943	densities	_
12-18	1944-1946	as	_
12-19	1947-1951	well	_
12-20	1952-1954	as	_
12-21	1955-1982	dopamine-synthesis-capacity	_
12-22	1983-1984	.	_

13-1	1985-1996	Conclusions	_
13-2	1997-1998	:	_
13-3	1999-2001	We	_
13-4	2002-2010	revealed	_
13-5	2011-2012	a	_
13-6	2013-2019	robust	_
13-7	2020-2031	association	_
13-8	2032-2039	between	_
13-9	2040-2049	intrinsic	_
13-10	2050-2060	functional	_
13-11	2061-2073	connectivity	_
13-12	2074-2080	within	_
13-13	2081-2089	networks	_
13-14	2090-2093	for	_
13-15	2094-2109	socio-affective	_
13-16	2110-2119	processes	_
13-17	2120-2123	and	_
13-18	2124-2127	the	_
13-19	2128-2137	cognitive	_
13-20	2138-2147	dimension	_
13-21	2148-2150	of	_
13-22	2151-2166	psychopathology	_
13-23	2167-2168	.	_

14-1	2169-2171	By	_
14-2	2172-2185	investigating	_
14-3	2186-2189	the	_
14-4	2190-2199	molecular	_
14-5	2200-2212	architecture	_
14-6	2213-2214	,	_
14-7	2215-2219	this	_
14-8	2220-2224	work	_
14-9	2225-2230	links	_
14-10	2231-2243	dopaminergic	_
14-11	2244-2247	and	_
14-12	2248-2260	serotonergic	_
14-13	2261-2268	systems	_
14-14	2269-2273	with	_
14-15	2274-2277	the	_
14-16	2278-2288	functional	_
14-17	2289-2299	topography	_
14-18	2300-2302	of	_
14-19	2303-2308	brain	_
14-20	2309-2317	networks	_
14-21	2318-2328	underlying	_
14-22	2329-2338	cognitive	_
14-23	2339-2347	symptoms	_
14-24	2348-2350	in	_
14-25	2351-2364	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
14-26	2365-2366	.	_

15-1	2367-2376	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
15-2	2377-2380	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
15-3	2381-2388	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
15-4	2389-2395	Sample	_
15-5	2396-2397	A	_
15-6	2398-2403	total	_
15-7	2404-2406	of	_
15-8	2407-2410	147	_
15-9	2411-2424	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
15-10	2425-2433	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
15-11	2434-2438	from	_
15-12	2439-2444	seven	_
15-13	2445-2452	centers	_
15-14	2453-2460	located	_
15-15	2461-2463	in	_
15-16	2464-2470	Europe	_
15-17	2471-2474	and	_
15-18	2475-2478	the	_
15-19	2479-2482	USA	_
15-20	2483-2494	represented	_
15-21	2495-2498	the	_
15-22	2499-2503	main	_
15-23	2504-2510	sample	_
15-24	2511-2512	(	_
15-25	2513-2518	Table	_
15-26	2519-2521	S1	_
15-27	2522-2523	;	_
15-28	2524-2534	Supplement	_
15-29	2535-2536	)	_
15-30	2537-2538	.	_

16-1	2539-2544	These	_
16-2	2545-2550	sites	_
16-3	2551-2559	differed	_
16-4	2560-2573	significantly	_
16-5	2574-2576	in	_
16-6	2577-2584	illness	_
16-7	2585-2593	duration	_
16-8	2594-2595	(	_
16-9	2596-2597	p	_
16-10	2598-2599	<	_
16-11	2600-2605	0.001	_
16-12	2606-2607	)	_
16-13	2608-2609	(	_
16-14	2610-2615	Table	_
16-15	2616-2618	S1	_
16-16	2619-2620	)	_
16-17	2621-2622	.	_

17-1	2623-2625	An	_
17-2	2626-2637	independent	_
17-3	2638-2644	sample	_
17-4	2645-2649	with	_
17-5	2650-2653	117	_
17-6	2654-2667	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
17-7	2668-2676	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
17-8	2677-2678	(	_
17-9	2679-2684	Table	_
17-10	2685-2687	S2	_
17-11	2688-2689	;	_
17-12	2690-2700	Supplement	_
17-13	2701-2702	)	_
17-14	2703-2712	retrieved	_
17-15	2713-2717	from	_
17-16	2718-2721	the	_
17-17	2722-2743	Bipolar-Schizophrenia	_
17-18	2744-2751	Network	_
17-19	2752-2754	on	_
17-20	2755-2767	Intermediate	_
17-21	2768-2778	Phenotypes	_
17-22	2779-2780	(	_
17-23	2781-2787	B-SNIP	_
17-24	2788-2789	)	_
17-25	2790-2798	database	_
17-26	2799-2802	was	_
17-27	2803-2807	used	_
17-28	2808-2811	for	_
17-29	2812-2823	independent	_
17-30	2824-2829	model	_
17-31	2830-2840	validation	_
17-32	2841-2842	.	_

18-1	2843-2846	For	_
18-2	2847-2851	both	_
18-3	2852-2859	samples	_
18-4	2860-2861	,	_
18-5	2862-2871	diagnosis	_
18-6	2872-2874	of	_
18-7	2875-2888	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
18-8	2889-2892	was	_
18-9	2893-2904	established	_
18-10	2905-2910	based	_
18-11	2911-2913	on	_
18-12	2914-2917	the	_
18-13	2918-2924	DSM-IV	_
18-14	2925-2926	,	_
18-15	2927-2930	the	_
18-16	2931-2940	DSM-IV-TR	_
18-17	2941-2942	,	_
18-18	2943-2945	or	_
18-19	2946-2949	the	_
18-20	2950-2956	ICD-10	_
18-21	2957-2965	criteria	_
18-22	2966-2967	(	_
18-23	2968-2971	see	_
18-24	2972-2982	Supplement	_
18-25	2983-2986	and	_
18-26	2987-2988	[	_
18-27	2989-2990	6	_
18-28	2991-2992	]	_
18-29	2993-2994	)	_
18-30	2995-2996	.	_

19-1	2997-3002	These	_
19-2	3003-3016	international	_
19-3	3017-3025	datasets	_
19-4	3026-3031	cover	_
19-5	3032-3033	a	_
19-6	3034-3039	broad	_
19-7	3040-3045	range	_
19-8	3046-3048	of	_
19-9	3049-3057	clinical	_
19-10	3058-3064	states	_
19-11	3065-3066	,	_
19-12	3067-3075	settings	_
19-13	3076-3077	,	_
19-14	3078-3081	and	_
19-15	3082-3089	medical	_
19-16	3090-3097	systems	_
19-17	3098-3099	,	_
19-18	3100-3112	facilitating	_
19-19	3113-3127	identification	_
19-20	3128-3130	of	_
19-21	3131-3137	robust	_
19-22	3138-3153	network-symptom	_
19-23	3154-3166	associations	_
19-24	3167-3168	.	_

20-1	3169-3176	Current	_
20-2	3177-3181	drug	_
20-3	3182-3189	dosages	_
20-4	3190-3192	of	_
20-5	3193-3206	antipsychotic	_
20-6	3207-3217	medication	_
20-7	3218-3222	were	_
20-8	3223-3244	olanzapine-equivalent	_
20-9	3245-3256	transformed	_
20-10	3257-3258	.	_

21-1	3259-3262	For	_
21-2	3263-3267	each	_
21-3	3268-3272	site	_
21-4	3273-3274	,	_
21-5	3275-3283	subjects	_
21-6	3284-3288	gave	_
21-7	3289-3296	written	_
21-8	3297-3305	informed	_
21-9	3306-3313	consent	_
21-10	3314-3317	and	_
21-11	3318-3323	study	_
21-12	3324-3332	approval	_
21-13	3333-3336	was	_
21-14	3337-3342	given	_
21-15	3343-3345	by	_
21-16	3346-3349	the	_
21-17	3350-3360	respective	_
21-18	3361-3367	ethics	_
21-19	3368-3392	committees/institutional	_
21-20	3393-3399	review	_
21-21	3400-3406	boards	_
21-22	3407-3408	.	_

22-1	3409-3417	Approval	_
22-2	3418-3421	for	_
22-3	3422-3428	pooled	_
22-4	3429-3440	re-analysis	_
22-5	3441-3444	was	_
22-6	3445-3453	provided	_
22-7	3454-3456	by	_
22-8	3457-3460	the	_
22-9	3461-3467	ethics	_
22-10	3468-3477	committee	_
22-11	3478-3480	of	_
22-12	3481-3484	the	_
22-13	3485-3495	University	_
22-14	3496-3498	of	_
22-15	3499-3509	Düsseldorf	_
22-16	3510-3511	,	_
22-17	3512-3519	Germany	_
22-18	3520-3521	.	_

23-1	3522-3533	Calculation	_
23-2	3534-3536	of	_
23-3	3537-3548	dimensional	_
23-4	3549-3556	symptom	_
23-5	3557-3563	scores	_
23-6	3564-3572	Severity	_
23-7	3573-3575	of	_
23-8	3576-3591	psychopathology	_
23-9	3592-3595	was	_
23-10	3596-3604	assessed	_
23-11	3605-3610	using	_
23-12	3611-3614	the	_
23-13	3615-3620	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
23-14	3621-3622	.	_

24-1	3623-3626	The	_
24-2	3627-3629	30	_
24-3	3630-3635	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
24-4	3636-3641	items	_
24-5	3642-3646	were	_
24-6	3647-3657	compressed	_
24-7	3658-3662	into	_
24-8	3663-3667	four	_
24-9	3668-3669	(	_
24-10	3670-3678	negative	_
24-11	3679-3680	,	_
24-12	3681-3689	positive	_
24-13	3690-3691	,	_
24-14	3692-3701	affective	_
24-15	3702-3703	,	_
24-16	3704-3707	and	_
24-17	3708-3717	cognitive	_
24-18	3718-3719	)	_
24-19	3720-3727	symptom	_
24-20	3728-3738	dimensions	_
24-21	3739-3740	(	_
24-22	3741-3747	Figure	_
24-23	3748-3751	S1A	_
24-24	3752-3753	)	_
24-25	3754-3764	identified	_
24-26	3765-3767	in	_
24-27	3768-3771	our	_
24-28	3772-3777	prior	_
24-29	3778-3791	factorization	_
24-30	3792-3800	analysis	_
24-31	3801-3803	on	_
24-32	3804-3807	two	_
24-33	3808-3813	large	_
24-34	3814-3815	,	_
24-35	3816-3826	multi-site	_
24-36	3827-3840	schizophrenia	_
24-37	3841-3848	samples	_
24-38	3849-3851	as	_
24-39	3852-3858	stable	_
24-40	3859-3862	and	_
24-41	3863-3881	well-generalizable	_
24-42	3882-3888	across	_
24-43	3889-3900	populations	_
24-44	3901-3902	,	_
24-45	3903-3911	settings	_
24-46	3912-3913	,	_
24-47	3914-3917	and	_
24-48	3918-3925	medical	_
24-49	3926-3933	systems	_
24-50	3934-3935	.	_

25-1	3936-3940	Each	_
25-2	3941-3952	dimensional	_
25-3	3953-3958	score	_
25-4	3959-3962	for	_
25-5	3963-3965	an	_
25-6	3966-3976	individual	_
25-7	3977-3980	was	_
25-8	3981-3991	calculated	_
25-9	3992-3994	as	_
25-10	3995-3998	the	_
25-11	3999-4002	dot	_
25-12	4003-4010	product	_
25-13	4011-4018	between	_
25-14	4019-4022	the	_
25-15	4023-4035	coefficients	_
25-16	4036-4042	loaded	_
25-17	4043-4045	on	_
25-18	4046-4049	the	_
25-19	4050-4060	particular	_
25-20	4061-4070	dimension	_
25-21	4071-4077	within	_
25-22	4078-4081	the	_
25-23	4082-4103	dimensional-structure	_
25-24	4104-4105	(	_
25-25	4106-4112	Figure	_
25-26	4113-4115	S1	_
25-27	4116-4117	)	_
25-28	4118-4121	and	_
25-29	4122-4125	the	_
25-30	4126-4128	30	_
25-31	4129-4134	PANSS	_
25-32	4135-4139	item	_
25-33	4140-4146	scores	_
25-34	4147-4149	of	_
25-35	4150-4154	that	_
25-36	4155-4165	individual	_
25-37	4166-4167	(	_
25-38	4168-4170	as	_
25-39	4171-4182	implemented	_
25-40	4183-4185	in	_
25-41	4186-4190	DCTS	_
25-42	4191-4192	:	_
25-43	4193-4197	http	_
25-44	4198-4199	:	_
25-45	4200-4227	//webtools.inm7.de/sczDCTS/	_
25-46	4228-4229	)	_
25-47	4230-4231	.	_

26-1	4232-4238	Higher	_
26-2	4239-4245	scores	_
26-3	4246-4248	on	_
26-4	4249-4250	a	_
26-5	4251-4260	dimension	_
26-6	4261-4269	indicate	_
26-7	4270-4281	more-severe	_
26-8	4282-4290	symptoms	_
26-9	4291-4292	(	_
26-10	4293-4299	Figure	_
26-11	4300-4303	S1B	_
26-12	4304-4305	)	_
26-13	4306-4307	.	_

27-1	4308-4318	Definition	_
27-2	4319-4321	of	_
27-3	4322-4332	functional	_
27-4	4333-4338	brain	_
27-5	4339-4347	networks	_
27-6	4348-4357	Seventeen	_
27-7	4358-4368	functional	_
27-8	4369-4377	networks	_
27-9	4378-4379	,	_
27-10	4380-4385	which	_
27-11	4386-4391	cover	_
27-12	4392-4393	a	_
27-13	4394-4399	broad	_
27-14	4400-4405	range	_
27-15	4406-4408	of	_
27-16	4409-4416	domains	_
27-17	4417-4427	reflecting	_
27-18	4428-4437	cognitive	_
27-19	4438-4439	,	_
27-20	4440-4455	socio-affective	_
27-21	4456-4457	,	_
27-22	4458-4461	and	_
27-23	4462-4475	sensory-motor	_
27-24	4476-4485	functions	_
27-25	4486-4490	that	_
27-26	4491-4495	have	_
27-27	4496-4500	been	_
27-28	4501-4511	implicated	_
27-29	4512-4514	in	_
27-30	4515-4528	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
27-31	4529-4530	,	_
27-32	4531-4535	were	_
27-33	4536-4544	employed	_
27-34	4545-4546	(	_
27-35	4547-4552	Table	_
27-36	4553-4555	S3	_
27-37	4556-4557	)	_
27-38	4558-4559	.	_

28-1	4560-4565	These	_
28-2	4566-4574	networks	_
28-3	4575-4579	were	_
28-4	4580-4585	based	_
28-5	4586-4588	on	_
28-6	4589-4605	coordinate-based	_
28-7	4606-4619	meta-analyses	_
28-8	4620-4623	and	_
28-9	4624-4633	represent	_
28-10	4634-4641	regions	_
28-11	4642-4655	demonstrating	_
28-12	4656-4666	convergent	_
28-13	4667-4678	activations	_
28-14	4679-4689	associated	_
28-15	4690-4694	with	_
28-16	4695-4703	specific	_
28-17	4704-4714	functional	_
28-18	4715-4722	domains	_
28-19	4723-4729	across	_
28-20	4730-4734	many	_
28-21	4735-4740	prior	_
28-22	4741-4750	task-fMRI	_
28-23	4751-4758	studies	_
28-24	4759-4760	.	_

29-1	4761-4765	They	_
29-2	4766-4771	hence	_
29-3	4772-4779	provide	_
29-4	4780-4783	the	_
29-5	4784-4788	best	_
29-6	4789-4790	“	_
29-7	4791-4792	a	_
29-8	4793-4799	priori	_
29-9	4800-4801	”	_
29-10	4802-4810	estimate	_
29-11	4811-4813	of	_
29-12	4814-4817	the	_
29-13	4818-4826	location	_
29-14	4827-4829	of	_
29-15	4830-4838	specific	_
29-16	4839-4849	functional	_
29-17	4850-4858	networks	_
29-18	4859-4862	and	_
29-19	4863-4868	hence	_
29-20	4869-4873	here	_
29-21	4874-4882	assessed	_
29-22	4883-4885	by	_
29-23	4886-4899	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
29-24	4900-4904	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
29-25	4905-4907	in	_
29-26	4908-4911	new	_
29-27	4912-4920	subjects	_
29-28	4921-4922	.	_

30-1	4923-4926	For	_
30-2	4927-4938	convenience	_
30-3	4939-4940	,	_
30-4	4941-4943	we	_
30-5	4944-4951	grouped	_
30-6	4952-4957	these	_
30-7	4958-4960	17	_
30-8	4961-4969	networks	_
30-9	4970-4974	into	_
30-10	4975-4978	six	_
30-11	4979-4984	broad	_
30-12	4985-4995	functional	_
30-13	4996-5003	domains	_
30-14	5004-5005	(	_
30-15	5006-5012	Figure	_
30-16	5013-5014	1	_
30-17	5015-5016	&	_
30-18	5017-5022	Table	_
30-19	5023-5025	S3	_
30-20	5026-5027	)	_
30-21	5028-5029	,	_
30-22	5030-5036	though	_
30-23	5037-5039	it	_
30-24	5040-5044	must	_
30-25	5045-5047	be	_
30-26	5048-5056	stressed	_
30-27	5057-5061	that	_
30-28	5062-5066	each	_
30-29	5067-5074	network	_
30-30	5075-5078	was	_
30-31	5079-5087	analyzed	_
30-32	5088-5098	separately	_
30-33	5099-5100	.	_

31-1	5101-5105	FMRI	_
31-2	5106-5110	data	_
31-3	5111-5121	processing	_
31-4	5122-5125	All	_
31-5	5126-5139	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
31-6	5140-5144	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
31-7	5145-5150	scans	_
31-8	5151-5152	(	_
31-9	5153-5159	Tables	_
31-10	5160-5162	S4	_
31-11	5163-5164	&	_
31-12	5165-5167	S5	_
31-13	5168-5169	)	_
31-14	5170-5174	were	_
31-15	5175-5187	preprocessed	_
31-16	5188-5193	using	_
31-17	5194-5199	SPM12	_
31-18	5200-5201	(	_
31-19	5202-5206	http	_
31-20	5207-5208	:	_
31-21	5209-5236	//www.fil.ion.ucl.ac.uk/spm	_
31-22	5237-5238	)	_
31-23	5239-5240	(	_
31-24	5241-5244	see	_
31-25	5245-5246	[	_
31-26	5247-5248	6	_
31-27	5249-5250	]	_
31-28	5251-5254	and	_
31-29	5255-5265	Supplement	_
31-30	5266-5267	)	_
31-31	5268-5269	.	_

32-1	5270-5275	After	_
32-2	5276-5285	excluding	_
32-3	5286-5294	subjects	_
32-4	5295-5299	with	_
32-5	5300-5309	excessive	_
32-6	5310-5321	head-motion	_
32-7	5322-5324	or	_
32-8	5325-5329	poor	_
32-9	5330-5335	image	_
32-10	5336-5343	quality	_
32-11	5344-5345	(	_
32-12	5346-5348	cf	_
32-13	5349-5350	.	_

33-1	5351-5361	Supplement	_
33-2	5362-5363	)	_
33-3	5364-5365	,	_
33-4	5366-5369	126	_
33-5	5370-5373	and	_
33-6	5374-5377	100	_
33-7	5378-5391	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
33-8	5392-5400	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
33-9	5401-5405	were	_
33-10	5406-5414	retained	_
33-11	5415-5417	in	_
33-12	5418-5421	the	_
33-13	5422-5426	main	_
33-14	5427-5430	and	_
33-15	5431-5434	the	_
33-16	5435-5441	B-SNIP	_
33-17	5442-5452	validation	_
33-18	5453-5459	sample	_
33-19	5460-5461	,	_
33-20	5462-5474	respectively	_
33-21	5475-5476	(	_
33-22	5477-5482	Table	_
33-23	5483-5484	1	_
33-24	5485-5486	)	_
33-25	5487-5488	.	_

34-1	5489-5493	Head	_
34-2	5494-5500	motion	_
34-3	5501-5509	differed	_
34-4	5510-5523	significantly	_
34-5	5524-5531	between	_
34-6	5532-5535	the	_
34-7	5536-5541	sites	_
34-8	5542-5545	but	_
34-9	5546-5549	did	_
34-10	5550-5553	not	_
34-11	5554-5563	correlate	_
34-12	5564-5568	with	_
34-13	5569-5572	the	_
34-14	5573-5582	residuals	_
34-15	5583-5585	of	_
34-16	5586-5589	any	_
34-17	5590-5597	symptom	_
34-18	5598-5608	dimensions	_
34-19	5609-5614	after	_
34-20	5615-5624	adjusting	_
34-21	5625-5628	for	_
34-22	5629-5644	age/gender/site	_
34-23	5645-5646	.	_

35-1	5647-5652	Still	_
35-2	5653-5654	,	_
35-3	5655-5657	we	_
35-4	5658-5666	adjusted	_
35-5	5667-5678	head-motion	_
35-6	5679-5686	effects	_
35-7	5687-5689	in	_
35-8	5690-5700	predictive	_
35-9	5701-5709	modeling	_
35-10	5710-5712	as	_
35-11	5713-5714	a	_
35-12	5715-5727	conservative	_
35-13	5728-5736	approach	_
35-14	5737-5739	to	_
35-15	5740-5744	rule	_
35-16	5745-5748	out	_
35-17	5749-5750	(	_
35-18	5751-5754	any	_
35-19	5755-5756	)	_
35-20	5757-5765	possible	_
35-21	5766-5780	predictability	_
35-22	5781-5786	based	_
35-23	5787-5789	on	_
35-24	5790-5798	movement	_
35-25	5799-5800	.	_

36-1	5801-5806	White	_
36-2	5807-5813	matter	_
36-3	5814-5817	and	_
36-4	5818-5821	CSF	_
36-5	5822-5829	signals	_
36-6	5830-5832	as	_
36-7	5833-5837	well	_
36-8	5838-5840	as	_
36-9	5841-5843	24	_
36-10	5844-5855	head-motion	_
36-11	5856-5866	parameters	_
36-12	5867-5871	were	_
36-13	5872-5881	regressed	_
36-14	5882-5885	out	_
36-15	5886-5890	from	_
36-16	5891-5894	the	_
36-17	5895-5902	overall	_
36-18	5903-5907	fMRI	_
36-19	5908-5919	time-series	_
36-20	5920-5923	but	_
36-21	5924-5927	the	_
36-22	5928-5934	global	_
36-23	5935-5939	mean	_
36-24	5940-5947	signals	_
36-25	5948-5952	were	_
36-26	5953-5956	not	_
36-27	5957-5964	removed	_
36-28	5965-5970	given	_
36-29	5971-5978	ongoing	_
36-30	5979-5992	controversies	_
36-31	5993-5994	.	_

37-1	5995-6001	Voxels	_
37-2	6002-6008	within	_
37-3	6009-6010	a	_
37-4	6011-6012	6	_
37-5	6013-6015	mm	_
37-6	6016-6022	sphere	_
37-7	6023-6029	around	_
37-8	6030-6034	each	_
37-9	6035-6037	of	_
37-10	6038-6041	the	_
37-11	6042-6059	meta-analytically	_
37-12	6060-6067	derived	_
37-13	6068-6083	peak-activation	_
37-14	6084-6094	coordinate	_
37-15	6095-6101	formed	_
37-16	6102-6103	a	_
37-17	6104-6108	node	_
37-18	6109-6110	.	_

38-1	6111-6114	The	_
38-2	6115-6120	first	_
38-3	6121-6133	eigenvariate	_
38-4	6134-6136	of	_
38-5	6137-6140	the	_
38-6	6141-6152	time-series	_
38-7	6153-6157	from	_
38-8	6158-6161	all	_
38-9	6162-6165	the	_
38-10	6166-6172	voxels	_
38-11	6173-6179	within	_
38-12	6180-6184	each	_
38-13	6185-6189	node	_
38-14	6190-6193	was	_
38-15	6194-6204	calculated	_
38-16	6205-6207	as	_
38-17	6208-6211	the	_
38-18	6212-6220	regional	_
38-19	6221-6235	characteristic	_
38-20	6236-6247	time-series	_
38-21	6248-6258	containing	_
38-22	6259-6265	better	_
38-23	6266-6281	signal-to-noise	_
38-24	6282-6287	ratio	_
38-25	6288-6292	than	_
38-26	6293-6296	the	_
38-27	6297-6301	peak	_
38-28	6302-6307	voxel	_
38-29	6308-6313	alone	_
38-30	6314-6315	.	_

39-1	6316-6319	For	_
39-2	6320-6324	each	_
39-3	6325-6332	network	_
39-4	6333-6334	,	_
39-5	6335-6342	Pearson	_
39-6	6343-6344	’	_
39-7	6345-6346	s	_
39-8	6347-6358	correlation	_
39-9	6359-6362	was	_
39-10	6363-6373	calculated	_
39-11	6374-6381	between	_
39-12	6382-6385	the	_
39-13	6386-6400	characteristic	_
39-14	6401-6412	time-series	_
39-15	6413-6416	for	_
39-16	6417-6421	each	_
39-17	6422-6426	pair	_
39-18	6427-6429	of	_
39-19	6430-6433	the	_
39-20	6434-6439	nodes	_
39-21	6440-6449	resulting	_
39-22	6450-6452	in	_
39-23	6453-6455	an	_
39-24	6456-6457	N	_
39-25	6458-6459	x	_
39-26	6460-6461	N	_
39-27	6462-6468	matrix	_
39-28	6469-6471	of	_
39-29	6472-6485	resting-state	_
39-30	6486-6496	functional	_
39-31	6497-6509	connectivity	_
39-32	6510-6511	(	_
39-33	6512-6517	rs-FC	_
39-34	6518-6519	)	_
39-35	6520-6521	.	_

40-1	6522-6525	The	_
40-2	6526-6531	upper	_
40-3	6532-6540	triangle	_
40-4	6541-6543	of	_
40-5	6544-6547	the	_
40-6	6548-6557	resulting	_
40-7	6558-6570	connectivity	_
40-8	6571-6577	matrix	_
40-9	6578-6581	was	_
40-10	6582-6591	extracted	_
40-11	6592-6593	,	_
40-12	6594-6604	linearized	_
40-13	6605-6608	and	_
40-14	6609-6615	Fisher	_
40-15	6616-6617	’	_
40-16	6618-6619	s	_
40-17	6620-6633	Z-transformed	_
40-18	6634-6636	to	_
40-19	6637-6644	provide	_
40-20	6645-6648	the	_
40-21	6649-6657	features	_
40-22	6658-6661	for	_
40-23	6662-6665	our	_
40-24	6666-6676	predictive	_
40-25	6677-6685	modeling	_
40-26	6686-6687	.	_

41-1	6688-6698	Prediction	_
41-2	6699-6701	of	_
41-3	6702-6709	symptom	_
41-4	6710-6720	dimensions	_
41-5	6721-6726	using	_
41-6	6727-6734	network	_
41-7	6735-6740	rs-FC	_
41-8	6741-6754	Multivariable	_
41-9	6755-6765	regression	_
41-10	6766-6769	via	_
41-11	6770-6771	a	_
41-12	6772-6781	relevance	_
41-13	6782-6788	vector	_
41-14	6789-6796	machine	_
41-15	6797-6798	(	_
41-16	6799-6802	RVM	_
41-17	6803-6804	)	_
41-18	6805-6808	was	_
41-19	6809-6820	implemented	_
41-20	6821-6824	and	_
41-21	6825-6834	evaluated	_
41-22	6835-6840	using	_
41-23	6841-6845	500x	_
41-24	6846-6861	repeated10-fold	_
41-25	6862-6878	cross-validation	_
41-26	6879-6880	,	_
41-27	6881-6893	individually	_
41-28	6894-6897	for	_
41-29	6898-6902	each	_
41-30	6903-6914	combination	_
41-31	6915-6917	of	_
41-32	6918-6928	functional	_
41-33	6929-6936	network	_
41-34	6937-6940	and	_
41-35	6941-6948	symptom	_
41-36	6949-6958	dimension	_
41-37	6959-6961	in	_
41-38	6962-6965	the	_
41-39	6966-6970	main	_
41-40	6971-6977	sample	_
41-41	6978-6979	.	_

42-1	6980-6985	Using	_
42-2	6986-6990	each	_
42-3	6991-6998	network	_
42-4	6999-7011	individually	_
42-5	7012-7014	in	_
42-6	7015-7018	the	_
42-7	7019-7024	model	_
42-8	7025-7028	was	_
42-9	7029-7037	intended	_
42-10	7038-7040	to	_
42-11	7041-7047	ensure	_
42-12	7048-7051	the	_
42-13	7052-7062	functional	_
42-14	7063-7074	specificity	_
42-15	7075-7077	of	_
42-16	7078-7081	our	_
42-17	7082-7089	results	_
42-18	7090-7091	.	_

43-1	7092-7103	Importantly	_
43-2	7104-7105	,	_
43-3	7106-7109	RVM	_
43-4	7110-7112	is	_
43-5	7113-7114	a	_
43-6	7115-7121	sparse	_
43-7	7122-7130	learning	_
43-8	7131-7137	method	_
43-9	7138-7139	,	_
43-10	7140-7144	i.e.	_
43-11	7145-7146	,	_
43-12	7147-7151	only	_
43-13	7152-7153	a	_
43-14	7154-7157	few	_
43-15	7158-7160	of	_
43-16	7161-7164	the	_
43-17	7165-7172	learned	_
43-18	7173-7180	feature	_
43-19	7181-7188	weights	_
43-20	7189-7192	are	_
43-21	7193-7201	non-zero	_
43-22	7202-7203	,	_
43-23	7204-7211	lending	_
43-24	7212-7228	interpretability	_
43-25	7229-7231	as	_
43-26	7232-7234	to	_
43-27	7235-7240	which	_
43-28	7241-7249	features	_
43-29	7250-7251	(	_
43-30	7252-7263	connections	_
43-31	7264-7265	)	_
43-32	7266-7269	are	_
43-33	7270-7280	predictive	_
43-34	7281-7282	.	_

44-1	7283-7285	As	_
44-2	7286-7297	recommended	_
44-3	7298-7299	,	_
44-4	7300-7303	the	_
44-5	7304-7311	symptom	_
44-6	7312-7330	dimensional-scores	_
44-7	7331-7334	and	_
44-8	7335-7340	rs-FC	_
44-9	7341-7349	features	_
44-10	7350-7354	were	_
44-11	7355-7363	adjusted	_
44-12	7364-7367	for	_
44-13	7368-7379	confounding	_
44-14	7380-7387	effects	_
44-15	7388-7390	of	_
44-16	7391-7394	age	_
44-17	7395-7396	,	_
44-18	7397-7403	gender	_
44-19	7404-7405	,	_
44-20	7406-7410	site	_
44-21	7411-7412	,	_
44-22	7413-7416	and	_
44-23	7417-7428	head-motion	_
44-24	7429-7430	(	_
44-25	7431-7436	DVARS	_
44-26	7437-7438	)	_
44-27	7439-7440	.	_

45-1	7441-7443	To	_
45-2	7444-7449	avoid	_
45-3	7450-7462	data-leakage	_
45-4	7463-7469	within	_
45-5	7470-7486	cross-validation	_
45-6	7487-7488	,	_
45-7	7489-7497	confound	_
45-8	7498-7508	regression	_
45-9	7509-7515	models	_
45-10	7516-7520	were	_
45-11	7521-7528	learned	_
45-12	7529-7533	only	_
45-13	7534-7536	on	_
45-14	7537-7540	the	_
45-15	7541-7553	training-set	_
45-16	7554-7557	and	_
45-17	7558-7562	then	_
45-18	7563-7570	applied	_
45-19	7571-7573	on	_
45-20	7574-7578	both	_
45-21	7579-7587	training	_
45-22	7588-7591	and	_
45-23	7592-7596	test	_
45-24	7597-7601	data	_
45-25	7602-7603	.	_

46-1	7604-7607	The	_
46-2	7608-7611	RVM	_
46-3	7612-7617	model	_
46-4	7618-7625	trained	_
46-5	7626-7628	on	_
46-6	7629-7632	the	_
46-7	7633-7634	(	_
46-8	7635-7652	confound-adjusted	_
46-9	7653-7654	)	_
46-10	7655-7663	training	_
46-11	7664-7668	data	_
46-12	7669-7672	and	_
46-13	7673-7676	was	_
46-14	7677-7681	then	_
46-15	7682-7689	applied	_
46-16	7690-7692	to	_
46-17	7693-7696	the	_
46-18	7697-7698	(	_
46-19	7699-7716	confound-adjusted	_
46-20	7717-7718	)	_
46-21	7719-7727	held-out	_
46-22	7728-7732	data	_
46-23	7733-7734	.	_

47-1	7735-7740	Folds	_
47-2	7741-7745	were	_
47-3	7746-7756	stratified	_
47-4	7757-7759	to	_
47-5	7760-7771	accommodate	_
47-6	7772-7781	different	_
47-7	7782-7788	sample	_
47-8	7789-7794	sizes	_
47-9	7795-7801	across	_
47-10	7802-7807	sites	_
47-11	7808-7809	.	_

48-1	7810-7820	Prediction	_
48-2	7821-7832	performance	_
48-3	7833-7836	was	_
48-4	7837-7846	evaluated	_
48-5	7847-7852	using	_
48-6	7853-7860	Pearson	_
48-7	7861-7862	’	_
48-8	7863-7864	s	_
48-9	7865-7876	correlation	_
48-10	7877-7884	between	_
48-11	7885-7888	the	_
48-12	7889-7890	(	_
48-13	7891-7899	adjusted	_
48-14	7900-7901	)	_
48-15	7902-7908	scores	_
48-16	7909-7912	and	_
48-17	7913-7918	their	_
48-18	7919-7930	predictions	_
48-19	7931-7932	.	_

49-1	7933-7944	Significant	_
49-2	7945-7956	predictions	_
49-3	7957-7961	were	_
49-4	7962-7969	further	_
49-5	7970-7979	validated	_
49-6	7980-7983	for	_
49-7	7984-7989	their	_
49-8	7990-8006	generalizability	_
49-9	8007-8013	across	_
49-10	8014-8019	sites	_
49-11	8020-8025	using	_
49-12	8026-8044	leave-one-site-out	_
49-13	8045-8061	cross-validation	_
49-14	8062-8071	following	_
49-15	8072-8075	the	_
49-16	8076-8080	same	_
49-17	8081-8090	schematic	_
49-18	8091-8094	but	_
49-19	8095-8103	training	_
49-20	8104-8106	on	_
49-21	8107-8110	all	_
49-22	8111-8116	sites	_
49-23	8117-8120	but	_
49-24	8121-8124	one	_
49-25	8125-8128	and	_
49-26	8129-8136	testing	_
49-27	8137-8139	on	_
49-28	8140-8143	the	_
49-29	8144-8152	left-out	_
49-30	8153-8157	site	_
49-31	8158-8159	(	_
49-32	8160-8170	Supplement	_
49-33	8171-8172	)	_
49-34	8173-8174	.	_

50-1	8175-8186	Statistical	_
50-2	8187-8199	significance	_
50-3	8200-8202	of	_
50-4	8203-8206	the	_
50-5	8207-8229	cross-validation-based	_
50-6	8230-8242	correlations	_
50-7	8243-8246	was	_
50-8	8247-8257	determined	_
50-9	8258-8265	through	_
50-10	8266-8270	1000	_
50-11	8271-8283	permutations	_
50-12	8284-8286	by	_
50-13	8287-8296	shuffling	_
50-14	8297-8300	the	_
50-15	8301-8308	symptom	_
50-16	8309-8327	dimensional-scores	_
50-17	8328-8329	(	_
50-18	8330-8336	lowest	_
50-19	8337-8344	p=0.001	_
50-20	8345-8346	,	_
50-21	8347-8359	right-tailed	_
50-22	8360-8361	;	_
50-23	8362-8372	Supplement	_
50-24	8373-8374	)	_
50-25	8375-8376	.	_

51-1	8377-8387	Critically	_
51-2	8388-8389	,	_
51-3	8390-8392	we	_
51-4	8393-8402	validated	_
51-5	8403-8413	predictive	_
51-6	8414-8426	associations	_
51-7	8427-8436	confirmed	_
51-8	8437-8439	by	_
51-9	8440-8458	leave-one-site-out	_
51-10	8459-8475	cross-validation	_
51-11	8476-8478	in	_
51-12	8479-8482	the	_
51-13	8483-8494	independent	_
51-14	8495-8501	B-SNIP	_
51-15	8502-8508	sample	_
51-16	8509-8510	.	_

52-1	8511-8514	For	_
52-2	8515-8519	this	_
52-3	8520-8521	,	_
52-4	8522-8524	we	_
52-5	8525-8532	trained	_
52-6	8533-8536	RVM	_
52-7	8537-8543	models	_
52-8	8544-8546	on	_
52-9	8547-8550	the	_
52-10	8551-8564	significantly	_
52-11	8565-8575	predictive	_
52-12	8576-8584	networks	_
52-13	8585-8587	in	_
52-14	8588-8591	the	_
52-15	8592-8598	entire	_
52-16	8599-8603	main	_
52-17	8604-8610	sample	_
52-18	8611-8614	and	_
52-19	8615-8619	then	_
52-20	8620-8621	,	_
52-21	8622-8629	without	_
52-22	8630-8637	further	_
52-23	8638-8645	fitting	_
52-24	8646-8648	or	_
52-25	8649-8661	modification	_
52-26	8662-8663	,	_
52-27	8664-8671	applied	_
52-28	8672-8676	them	_
52-29	8677-8679	to	_
52-30	8680-8688	held-out	_
52-31	8689-8695	B-SNIP	_
52-32	8696-8700	data	_
52-33	8701-8702	.	_

53-1	8703-8709	Robust	_
53-2	8710-8722	associations	_
53-3	8723-8730	passing	_
53-4	8731-8735	this	_
53-5	8736-8742	strict	_
53-6	8743-8753	three-step	_
53-7	8754-8764	validation	_
53-8	8765-8774	procedure	_
53-9	8775-8779	were	_
53-10	8780-8784	then	_
53-11	8785-8792	further	_
53-12	8793-8801	assessed	_
53-13	8802-8804	as	_
53-14	8805-8814	described	_
53-15	8815-8820	below	_
53-16	8821-8822	.	_

54-1	8823-8825	In	_
54-2	8826-8834	addition	_
54-3	8835-8836	,	_
54-4	8837-8848	connections	_
54-5	8849-8855	within	_
54-6	8856-8859	the	_
54-7	8860-8868	networks	_
54-8	8869-8879	identified	_
54-9	8880-8884	with	_
54-10	8885-8891	robust	_
54-11	8892-8904	associations	_
54-12	8905-8909	with	_
54-13	8910-8918	symptoms	_
54-14	8919-8923	were	_
54-15	8924-8932	combined	_
54-16	8933-8935	to	_
54-17	8936-8940	test	_
54-18	8941-8944	the	_
54-19	8945-8953	possible	_
54-20	8954-8965	improvement	_
54-21	8966-8968	in	_
54-22	8969-8979	prediction	_
54-23	8980-8991	performance	_
54-24	8992-8993	.	_

55-1	8994-9001	Control	_
55-2	9002-9010	analyses	_
55-3	9011-9015	were	_
55-4	9016-9025	performed	_
55-5	9026-9028	by	_
55-6	9029-9038	repeating	_
55-7	9039-9042	all	_
55-8	9043-9053	validation	_
55-9	9054-9064	procedures	_
55-10	9065-9067	by	_
55-11	9068-9077	including	_
55-12	9078-9085	illness	_
55-13	9086-9094	duration	_
55-14	9095-9097	or	_
55-15	9098-9119	olanzapine-equivalent	_
55-16	9120-9126	dosage	_
55-17	9127-9129	as	_
55-18	9130-9139	confounds	_
55-19	9140-9141	.	_

56-1	9142-9145	For	_
56-2	9146-9156	comparison	_
56-3	9157-9158	,	_
56-4	9159-9160	i	_
56-5	9161-9162	)	_
56-6	9163-9165	we	_
56-7	9166-9175	predicted	_
56-8	9176-9179	the	_
56-9	9180-9185	three	_
56-10	9186-9191	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
56-11	9192-9201	subscales	_
56-12	9202-9203	(	_
56-13	9204-9212	positive	_
56-14	9213-9214	,	_
56-15	9215-9223	negative	_
56-16	9224-9225	,	_
56-17	9226-9229	and	_
56-18	9230-9237	general	_
56-19	9238-9253	psychopathology	_
56-20	9254-9255	)	_
56-21	9256-9261	using	_
56-22	9262-9265	the	_
56-23	9266-9270	same	_
56-24	9271-9281	three-step	_
56-25	9282-9292	validation	_
56-26	9293-9302	procedure	_
56-27	9303-9306	and	_
56-28	9307-9311	each	_
56-29	9312-9319	network	_
56-30	9320-9332	individually	_
56-31	9333-9335	as	_
56-32	9336-9338	in	_
56-33	9339-9342	our	_
56-34	9343-9347	main	_
56-35	9348-9356	analyses	_
56-36	9357-9358	,	_
56-37	9359-9362	and	_
56-38	9363-9365	ii	_
56-39	9366-9367	)	_
56-40	9368-9370	we	_
56-41	9371-9380	predicted	_
56-42	9381-9384	the	_
56-43	9385-9389	four	_
56-44	9390-9397	symptom	_
56-45	9398-9408	dimensions	_
56-46	9409-9414	using	_
56-47	9415-9431	whole-connectome	_
56-48	9432-9433	(	_
56-49	9434-9439	39060	_
56-50	9440-9451	connections	_
56-51	9452-9453	)	_
56-52	9454-9459	which	_
56-53	9460-9469	comprised	_
56-54	9470-9478	pairwise	_
56-55	9479-9491	connectivity	_
56-56	9492-9499	between	_
56-57	9500-9503	all	_
56-58	9504-9507	the	_
56-59	9508-9513	nodes	_
56-60	9514-9520	pooled	_
56-61	9521-9525	from	_
56-62	9526-9529	the	_
56-63	9530-9532	17	_
56-64	9533-9546	meta-analytic	_
56-65	9547-9555	networks	_
56-66	9556-9557	.	_

57-1	9558-9572	Identification	_
57-2	9573-9575	of	_
57-3	9576-9584	reliably	_
57-4	9585-9595	predictive	_
57-5	9596-9607	connections	_
57-6	9608-9611	and	_
57-7	9612-9623	subnetworks	_
57-8	9624-9627	The	_
57-9	9628-9637	intrinsic	_
57-10	9638-9645	feature	_
57-11	9646-9655	selection	_
57-12	9656-9658	in	_
57-13	9659-9662	RVM	_
57-14	9663-9670	through	_
57-15	9671-9674	its	_
57-16	9675-9681	sparse	_
57-17	9682-9690	modeling	_
57-18	9691-9694	was	_
57-19	9695-9704	leveraged	_
57-20	9705-9707	to	_
57-21	9708-9716	identify	_
57-22	9717-9725	reliably	_
57-23	9726-9736	predictive	_
57-24	9737-9748	connections	_
57-25	9749-9752	and	_
57-26	9753-9756	the	_
57-27	9757-9766	potential	_
57-28	9767-9778	subnetworks	_
57-29	9779-9785	formed	_
57-30	9786-9788	by	_
57-31	9789-9793	them	_
57-32	9794-9795	.	_

58-1	9796-9797	A	_
58-2	9798-9808	connection	_
58-3	9809-9812	was	_
58-4	9813-9823	identified	_
58-5	9824-9826	as	_
58-6	9827-9835	reliably	_
58-7	9836-9846	predictive	_
58-8	9847-9851	when	_
58-9	9852-9854	it	_
58-10	9855-9858	had	_
58-11	9859-9867	non-zero	_
58-12	9868-9875	weights	_
58-13	9876-9878	in	_
58-14	9879-9880	:	_
58-15	9881-9882	i	_
58-16	9883-9884	)	_
58-17	9885-9887	at	_
58-18	9888-9893	least	_
58-19	9894-9896	80	_
58-20	9897-9898	%	_
58-21	9899-9901	of	_
58-22	9902-9905	the	_
58-23	9906-9913	10-fold	_
58-24	9914-9930	cross-validation	_
58-25	9931-9942	repetitions	_
58-26	9943-9944	,	_
58-27	9945-9947	ii	_
58-28	9948-9949	)	_
58-29	9950-9952	at	_
58-30	9953-9958	least	_
58-31	9959-9962	six	_
58-32	9963-9966	out	_
58-33	9967-9969	of	_
58-34	9970-9973	the	_
58-35	9974-9979	seven	_
58-36	9980-9981	(	_
58-37	9982-9986	i.e.	_
58-38	9987-9988	,	_
58-39	9989-9990	>	_
58-40	9991-9993	80	_
58-41	9994-9995	%	_
58-42	9996-9997	)	_
58-43	9998-10016	leave-one-site-out	_
58-44	10017-10025	analyses	_
58-45	10026-10027	,	_
58-46	10028-10031	and	_
58-47	10032-10035	iii	_
58-48	10036-10037	)	_
58-49	10038-10041	the	_
58-50	10042-10048	models	_
58-51	10049-10056	trained	_
58-52	10057-10059	on	_
58-53	10060-10063	the	_
58-54	10064-10070	entire	_
58-55	10071-10075	main	_
58-56	10076-10082	sample	_
58-57	10083-10086	for	_
58-58	10087-10097	validation	_
58-59	10098-10100	in	_
58-60	10101-10107	B-SNIP	_
58-61	10108-10109	.	_

59-1	10110-10113	The	_
59-2	10114-10120	cutoff	_
59-3	10121-10123	of	_
59-4	10124-10126	80	_
59-5	10127-10128	%	_
59-6	10129-10131	is	_
59-7	10132-10141	suggested	_
59-8	10142-10144	as	_
59-9	10145-10146	a	_
59-10	10147-10159	conservative	_
59-11	10160-10169	threshold	_
59-12	10170-10172	in	_
59-13	10173-10177	both	_
59-14	10178-10182	real	_
59-15	10183-10186	and	_
59-16	10187-10196	simulated	_
59-17	10197-10201	data	_
59-18	10202-10203	.	_

60-1	10204-10206	To	_
60-2	10207-10213	assess	_
60-3	10214-10217	the	_
60-4	10218-10228	predictive	_
60-5	10229-10237	capacity	_
60-6	10238-10240	of	_
60-7	10241-10244	the	_
60-8	10245-10256	subnetworks	_
60-9	10257-10258	,	_
60-10	10259-10262	RVM	_
60-11	10263-10269	models	_
60-12	10270-10274	were	_
60-13	10275-10282	trained	_
60-14	10283-10288	using	_
60-15	10289-10292	the	_
60-16	10293-10298	rs-FC	_
60-17	10299-10301	of	_
60-18	10302-10305	the	_
60-19	10306-10317	subnetworks	_
60-20	10318-10320	on	_
60-21	10321-10324	the	_
60-22	10325-10329	main	_
60-23	10330-10336	sample	_
60-24	10337-10340	and	_
60-25	10341-10347	tested	_
60-26	10348-10350	in	_
60-27	10351-10357	B-SNIP	_
60-28	10358-10359	.	_

61-1	10360-10367	Spatial	_
61-2	10368-10379	correlation	_
61-3	10380-10384	with	_
61-4	10385-10405	receptor/transporter	_
61-5	10406-10415	densities	_
61-6	10416-10423	Finally	_
61-7	10424-10425	,	_
61-8	10426-10428	we	_
61-9	10429-10438	evaluated	_
61-10	10439-10442	the	_
61-11	10443-10456	topographical	_
61-12	10457-10469	relationship	_
61-13	10470-10477	between	_
61-14	10478-10490	network-node	_
61-15	10491-10499	location	_
61-16	10500-10503	and	_
61-17	10504-10507	the	_
61-18	10508-10520	distribution	_
61-19	10521-10523	of	_
61-20	10524-10531	several	_
61-21	10532-10552	receptor/transporter	_
61-22	10553-10560	systems	_
61-23	10561-10562	,	_
61-24	10563-10572	assessing	_
61-25	10573-10576	for	_
61-26	10577-10593	highly-expressed	_
61-27	10594-10616	receptors/transporters	_
61-28	10617-10619	in	_
61-29	10620-10623	the	_
61-30	10624-10634	identified	_
61-31	10635-10643	networks	_
61-32	10644-10652	relative	_
61-33	10653-10655	to	_
61-34	10656-10659	the	_
61-35	10660-10666	entire	_
61-36	10667-10672	brain	_
61-37	10673-10674	.	_

62-1	10675-10679	This	_
62-2	10680-10683	was	_
62-3	10684-10690	tested	_
62-4	10691-10693	by	_
62-5	10694-10703	comparing	_
62-6	10704-10707	the	_
62-7	10708-10715	average	_
62-8	10716-10736	receptor/transporter	_
62-9	10737-10744	density	_
62-10	10745-10751	across	_
62-11	10752-10755	all	_
62-12	10756-10761	nodes	_
62-13	10762-10768	within	_
62-14	10769-10770	a	_
62-15	10771-10776	given	_
62-16	10777-10784	network	_
62-17	10785-10792	against	_
62-18	10793-10794	a	_
62-19	10795-10812	null-distribution	_
62-20	10813-10818	based	_
62-21	10819-10821	on	_
62-22	10822-10826	1000	_
62-23	10827-10833	random	_
62-24	10834-10841	network	_
62-25	10842-10856	configurations	_
62-26	10857-10866	generated	_
62-27	10867-10869	by	_
62-28	10870-10885	re-distributing	_
62-29	10886-10889	the	_
62-30	10890-10895	nodes	_
62-31	10896-10906	throughout	_
62-32	10907-10910	the	_
62-33	10911-10915	grey	_
62-34	10916-10922	matter	_
62-35	10923-10928	while	_
62-36	10929-10939	preserving	_
62-37	10940-10943	the	_
62-38	10944-10956	between-node	_
62-39	10957-10966	distances	_
62-40	10967-10968	(	_
62-41	10969-10973	±6mm	_
62-42	10974-10983	tolerance	_
62-43	10984-10985	)	_
62-44	10986-10987	.	_

63-1	10988-10993	Seven	_
63-2	10994-11002	dopamine	_
63-3	11003-11006	and	_
63-4	11007-11016	serotonin	_
63-5	11017-11026	receptors	_
63-6	11027-11028	(	_
63-7	11029-11041	dopaminergic	_
63-8	11042-11043	:	_
63-9	11044-11046	D1	_
63-10	11047-11050	and	_
63-11	11051-11055	D2/3	_
63-12	11056-11057	;	_
63-13	11058-11070	serotonergic	_
63-14	11071-11072	:	_
63-15	11073-11079	5-HT1a	_
63-16	11080-11081	,	_
63-17	11082-11088	5-HT1b	_
63-18	11089-11090	,	_
63-19	11091-11094	and	_
63-20	11095-11101	5-HT2a	_
63-21	11102-11103	)	_
63-22	11104-11107	and	_
63-23	11108-11120	transporters	_
63-24	11121-11122	(	_
63-25	11123-11131	dopamine	_
63-26	11132-11143	transporter	_
63-27	11144-11147	and	_
63-28	11148-11153	5-HTT	_
63-29	11154-11163	serotonin	_
63-30	11164-11172	reuptake	_
63-31	11173-11184	transporter	_
63-32	11185-11186	)	_
63-33	11187-11188	,	_
63-34	11189-11197	together	_
63-35	11198-11202	with	_
63-36	11203-11209	F-DOPA	_
63-37	11210-11211	(	_
63-38	11212-11213	a	_
63-39	11214-11224	reflection	_
63-40	11225-11227	of	_
63-41	11228-11239	presynaptic	_
63-42	11240-11267	dopamine-synthesis-capacity	_
63-43	11268-11269	)	_
63-44	11270-11273	and	_
63-45	11274-11277	the	_
63-46	11278-11287	GABAergic	_
63-47	11288-11296	receptor	_
63-48	11297-11302	GABAa	_
63-49	11303-11307	were	_
63-50	11308-11320	investigated	_
63-51	11321-11322	.	_

64-1	11323-11328	While	_
64-2	11329-11332	all	_
64-3	11333-11340	systems	_
64-4	11341-11344	are	_
64-5	11345-11351	linked	_
64-6	11352-11354	to	_
64-7	11355-11368	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
64-8	11369-11370	,	_
64-9	11371-11373	we	_
64-10	11374-11378	here	_
64-11	11379-11385	tested	_
64-12	11386-11394	specific	_
64-13	11395-11417	receptors/transporters	_
64-14	11418-11419	.	_

65-1	11420-11427	Density	_
65-2	11428-11437	estimates	_
65-3	11438-11442	were	_
65-4	11443-11450	derived	_
65-5	11451-11455	from	_
65-6	11456-11463	average	_
65-7	11464-11469	group	_
65-8	11470-11474	maps	_
65-9	11475-11477	of	_
65-10	11478-11485	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
65-11	11486-11496	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
65-12	11497-11498	(	_
65-13	11499-11501	D1	_
65-14	11502-11503	:	_
65-15	11504-11508	N=13	_
65-16	11509-11510	;	_
65-17	11511-11515	D2/3	_
65-18	11516-11517	:	_
65-19	11518-11521	N=7	_
65-20	11522-11523	;	_
65-21	11524-11530	5-HT1a	_
65-22	11531-11532	:	_
65-23	11533-11537	N=35	_
65-24	11538-11539	;	_
65-25	11540-11546	5-HT1b	_
65-26	11547-11548	:	_
65-27	11549-11553	N=23	_
65-28	11554-11555	;	_
65-29	11556-11562	5-HT2a	_
65-30	11563-11564	:	_
65-31	11565-11569	N=19	_
65-32	11570-11571	;	_
65-33	11572-11577	5-HTT	_
65-34	11578-11579	:	_
65-35	11580-11584	N=18	_
65-36	11585-11586	;	_
65-37	11587-11595	dopamine	_
65-38	11596-11607	transporter	_
65-39	11608-11609	:	_
65-40	11610-11615	N=147	_
65-41	11616-11617	;	_
65-42	11618-11624	F-DOPA	_
65-43	11625-11626	:	_
65-44	11627-11631	N=12	_
65-45	11632-11633	;	_
65-46	11634-11639	GABAa	_
65-47	11640-11641	:	_
65-48	11642-11645	N=6	_
65-49	11646-11647	)	_
65-50	11648-11655	scanned	_
65-51	11656-11658	in	_
65-52	11659-11664	prior	_
65-53	11665-11677	multi-tracer	_
65-54	11678-11687	molecular	_
65-55	11688-11695	imaging	_
65-56	11696-11703	studies	_
65-57	11704-11705	(	_
65-58	11706-11716	Supplement	_
65-59	11717-11718	)	_
65-60	11719-11720	.	_

66-1	11721-11724	For	_
66-2	11725-11738	comparability	_
66-3	11739-11740	,	_
66-4	11741-11746	these	_
66-5	11747-11751	maps	_
66-6	11752-11753	,	_
66-7	11754-11756	in	_
66-8	11757-11763	MNI152	_
66-9	11764-11769	space	_
66-10	11770-11771	,	_
66-11	11772-11776	were	_
66-12	11777-11780	all	_
66-13	11781-11790	resampled	_
66-14	11791-11793	to	_
66-15	11794-11796	an	_
66-16	11797-11806	isotropic	_
66-17	11807-11810	2mm	_
66-18	11811-11818	spatial	_
66-19	11819-11829	resolution	_
66-20	11830-11832	as	_
66-21	11833-11835	in	_
66-22	11836-11839	our	_
66-23	11840-11844	fMRI	_
66-24	11845-11849	data	_
66-25	11850-11853	and	_
66-26	11854-11862	linearly	_
66-27	11863-11871	rescaled	_
66-28	11872-11874	to	_
66-29	11875-11880	0-100	_
66-30	11881-11882	.	_

67-1	11883-11894	Furthermore	_
67-2	11895-11896	,	_
67-3	11897-11900	the	_
67-4	11901-11914	significantly	_
67-5	11915-11921	higher	_
67-6	11922-11931	expressed	_
67-7	11932-11954	receptors/transporters	_
67-8	11955-11959	were	_
67-9	11960-11967	entered	_
67-10	11968-11972	into	_
67-11	11973-11974	a	_
67-12	11975-11982	spatial	_
67-13	11983-11994	correlation	_
67-14	11995-12003	analysis	_
67-15	12004-12014	calculated	_
67-16	12015-12017	as	_
67-17	12018-12022	rank	_
67-18	12023-12034	correlation	_
67-19	12035-12042	between	_
67-20	12043-12046	the	_
67-21	12047-12051	node	_
67-22	12052-12062	importance	_
67-23	12063-12069	scores	_
67-24	12070-12073	and	_
67-25	12074-12094	receptor/transporter	_
67-26	12095-12104	densities	_
67-27	12105-12115	calculated	_
67-28	12116-12119	for	_
67-29	12120-12125	these	_
67-30	12126-12131	nodes	_
67-31	12132-12133	(	_
67-32	12134-12140	Figure	_
67-33	12141-12143	4B	_
67-34	12144-12145	)	_
67-35	12146-12147	.	_

68-1	12148-12151	The	_
68-2	12152-12156	node	_
68-3	12157-12167	importance	_
68-4	12168-12173	score	_
68-5	12174-12177	was	_
68-6	12178-12188	calculated	_
68-7	12189-12191	by	_
68-8	12192-12199	summing	_
68-9	12200-12203	the	_
68-10	12204-12213	selection	_
68-11	12214-12223	frequency	_
68-12	12224-12226	of	_
68-13	12227-12230	the	_
68-14	12231-12242	connections	_
68-15	12243-12245	of	_
68-16	12246-12250	each	_
68-17	12251-12255	node	_
68-18	12256-12263	derived	_
68-19	12264-12268	from	_
68-20	12269-12272	the	_
68-21	12273-12281	repeated	_
68-22	12282-12289	10-fold	_
68-23	12290-12306	cross-validation	_
68-24	12307-12308	.	_

69-1	12309-12318	Bootstrap	_
69-2	12319-12327	analysis	_
69-3	12328-12331	was	_
69-4	12332-12341	conducted	_
69-5	12342-12344	to	_
69-6	12345-12351	ensure	_
69-7	12352-12362	robustness	_
69-8	12363-12364	.	_

70-1	12365-12367	To	_
70-2	12368-12377	establish	_
70-3	12378-12381	the	_
70-4	12382-12393	statistical	_
70-5	12394-12406	significance	_
70-6	12407-12409	of	_
70-7	12410-12411	a	_
70-8	12412-12419	spatial	_
70-9	12420-12431	correlation	_
70-10	12432-12439	against	_
70-11	12440-12446	chance	_
70-12	12447-12448	,	_
70-13	12449-12456	spatial	_
70-14	12457-12468	permutation	_
70-15	12469-12473	test	_
70-16	12474-12477	was	_
70-17	12478-12486	employed	_
70-18	12487-12492	where	_
70-19	12493-12496	the	_
70-20	12497-12501	null	_
70-21	12502-12514	distribution	_
70-22	12515-12518	was	_
70-23	12519-12528	estimated	_
70-24	12529-12534	based	_
70-25	12535-12537	on	_
70-26	12538-12541	the	_
70-27	12542-12554	correlations	_
70-28	12555-12562	between	_
70-29	12563-12566	the	_
70-30	12567-12571	node	_
70-31	12572-12582	importance	_
70-32	12583-12589	scores	_
70-33	12590-12593	for	_
70-34	12594-12595	a	_
70-35	12596-12601	given	_
70-36	12602-12609	network	_
70-37	12610-12613	and	_
70-38	12614-12617	the	_
70-39	12618-12623	nodal	_
70-40	12624-12644	receptor/transporter	_
70-41	12645-12654	densities	_
70-42	12655-12664	extracted	_
70-43	12665-12673	from1000	_
70-44	12674-12683	simulated	_
70-45	12684-12685	(	_
70-46	12686-12692	random	_
70-47	12693-12694	)	_
70-48	12695-12703	networks	_
70-49	12704-12705	(	_
70-50	12706-12716	Supplement	_
70-51	12717-12718	)	_
70-52	12719-12720	.	_

